Építés alatt – nem éles oldal
Belépés
Csak meghívásos2. fázis

Knee Pain Ejiao Paste for Knee Osteoarthritis

A legfontosabb adatok

Ki végzi
ShuGuang Hospital
Azonosító
Állapot
Csak meghívásos
Fázis
2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2026. márc. 30.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Knee Pain Ejiao Paste
  • Knee Pain Ejiao-free Clear Paste
A regiszteradat frissítve
2026. június 5.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with painful knee osteoarthritis (wear of the knee joint). In Chinese medicine terms, they must also have a Qi and Blood Deficiency Pattern.

Életkor
40 to 75 years
Nem
All sexes
A betegség stádiuma
Knee osteoarthritis in one or both knees. The target knee has Kellgren-Lawrence grade I-III on X-ray. Pain score (NRS) in the target knee is ≥4, and at least 1 WOMAC pain item is ≥40 mm. BMI ≤32 kg/m².
Korábbi kezelés
No other osteoarthritis medicines or therapies within one week before screening, except celecoxib tablets. No glucosamine, chondroitin or similar within 4 weeks. No knee joint injections within 3 months. No arthroscopy or lavage of the target knee within 6 months. No past knee replacement or other listed knee surgery.

A részvétel fő kizáró okai

  • Other joint diseases such as gout or rheumatoid arthritis, or nerve-related knee pain
  • Serious heart, brain blood vessel or gut disease, or poorly controlled high blood pressure (≥160/100 mmHg)
  • ALT or AST >1.5 times the upper limit of normal, or creatinine above normal
  • Pregnant or breastfeeding women, or planning pregnancy during the study and 3 months after
  • Alcohol or drug abuse, intellectual disability, psychosis or neurosis

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Meets the diagnostic criteria for knee osteoarthritis (OA), with unilateral or bilateral knee involvement
  • Prior to randomization, the NRS pain score of the target knee joint ≥4, and the NRS score of the contralateral knee joint is not higher than that of the target knee joint; among the 5 pain items on the WOMAC, at least 1 item scores ≥40 mm
  • Body Mass Index (BMI) ≤32 kg/m²
  • Meets the diagnostic criteria for Qi and Blood Deficiency Pattern
  • Age between 40 and 75 years inclusive (40 years ≤ age ≤ 75 years), male or female
  • The Kellgren-Lawrence grading of the target knee joint is grade I-III, and the Kellgren-Lawrence grading of the contralateral knee joint is not higher than that of the target knee joint (in cases of unilateral disease, the affected side is the target knee joint; in cases of bilateral disease, the target knee joint must satisfy the above criteria)
  • Voluntarily participates in this clinical trial, provides informed consent, and signs the informed consent form

Ki nem vehet részt

  • Use of other Chinese or Western medicines or therapies for osteoarthritis within one week prior to screening (excluding celecoxib tablets): such as non-steroidal anti-inflammatory drugs (excluding aspirin at no more than 325mg daily for cardiovascular disease prevention) , analgesics (including opioids, non-steroidal anti-inflammatory drugs, cyclooxygenase-2 (COX-2) inhibitors, tramadol, ketamine, clonidine, gabapentin, pregabalin and/or cannabinoids), or traditional Chinese medicine formulations with similar therapeutic indications to Knee Pain Ejiao Paste (i.e., those possessing qi-tonifying and blood-nourishing effects)
  • Use within 4 weeks prior to screening of drugs that relieve osteoarthritis (OA) symptoms (such as glucosamine, chondroitin sulfate, diacerein, etc.), any nutritional supplements with potential activity on articular cartilage, systemic corticosteroids or immunosuppressive drugs (subjects requiring only inhaled corticosteroids for asthma treatment may be enrolled)
  • Invasive procedures such as arthroscopy or lavage of the target knee joint within 6 months before screening or planned during the study period
  • Previous or planned target knee joint replacement (partial or total), autologous osteochondral mosaicplasty, microfracture, meniscectomy, osteotomy or other surgery during the study period
  • Investigator-judged serious comorbid cardiovascular, cerebrovascular, gastrointestinal diseases, poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg), or other conditions that could affect the assessment of the investigational product's efficacy and safety
  • Known or suspected allergy to the investigational product, rescue medication, or any of their components
  • Subjects who participated in any interventional drug clinical trial and received the investigational drug within 3 months prior to enrollment, or who are within 5 half-lives (whichever is longer) of any other clinical trial drug
  • Other conditions exist that may confound the assessment of function and pain in the target knee joint, such as: systemic diseases that may involve the joints (e.g., gouty arthritis, rheumatoid arthritis, etc.), chronic inflammatory or connective tissue diseases, neurological disorders, Paget's disease involving the knee, localized pain resulting from radicular lumbar compression, and any other conditions that may interfere with the efficacy assessment
  • Known or suspected history of alcohol or drug abuse
  • Receipt of biological products or intra-articular drug injection therapy (e.g., glucocorticoids, sodium hyaluronate, medical chitosan, growth factors, platelet-rich plasma, stem cell therapy, etc.) within 3 months prior to screening
  • Laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN), or creatinine (Cr) >ULN
  • Planned change or new use of mobility aids (e.g., wheelchair, walker, cane or crutch) or need for lower limb prosthesis and/or structural knee brace during the study period
  • Pregnant or lactating women, or women of childbearing potential planning pregnancy from enrollment through 3 months after the end of the study
  • Intellectual disability, psychosis, or neurosis

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 40 és 75 év között vagy?

Helyszínek itt: Kína

  • Shanghai Municipal Hospital of Traditional Chinese MedicineShanghai, KínaCsak meghívásos
  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineShanghai, KínaCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

To explore the analgesic efficacy of Knee Pain Ejiao Paste in the treatment of knee osteoarthritis (Qi and Blood Deficiency Pattern) after 12 weeks, using an Ejiao-free clear paste as a parallel control and incorporating a synthetic external control.

A vizsgálat 2 csoportja

  • Knee Pain Ejiao PasteA vizsgált kezelés

    Knee Pain Ejiao Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and E Jiao (Colla Corii Asini, 350g); Instruction: It is recommended to take the medication at a fixed time each day.

  • Knee Pain Ejiao-free Clear PastePlacebo, összehasonlításként

    Knee Pain Ejiao-free Clear Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and Mu Tang Chun (Xylitol, 350g)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blind, Two-Control Clinical Study of Knee Pain Ejiao Paste in the Treatment of Knee Osteoarthritis (Qi and Blood Deficiency Pattern)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07504562: ki vehet részt
A regiszteradat frissítve
2026. június 5.